Table 3.
Outcomes of BeEAM Compared With BEAM According to Disease Type or Disease Status at ASCT.
| Endpoint | Disease | Disease status at ASCT | ||||||
|---|---|---|---|---|---|---|---|---|
| HL majoratity | NHL majoratity | CR majoratity | PR/SD/PD majoratity | |||||
| Pooled OR (95% CI) | P | Pooled OR (95% CI) | P | Pooled OR (95% CI) | P | Pooled OR (95% CI) | P | |
| OS | 0.70 (0.23–2.11) | 0.53 | 0.73 (0.51–1.04) | 0.08 | 0.46 (0.29–0.75) | 0.002 | 0.65 (0.25–1.73) | 0.39 |
| PFS | 0.65 (0.29–1.45) | 0.29 | 0.71 (0.51–0.97) | 0.03 | 0.52 (0.35–0.79) | 0.002 | 0.72 (0.34–1.53) | 0.38 |
| NRM | 1.11 (0.16–7.74) | 0.91 | 1.57 (0.76–3.27) | 0.22 | 0.70 (0.24–2.03) | 0.52 | 2.5 (0.59–10.55) | 0.68 |
| RR | 0.80 (0.38–1.67) | 0.55 | 0.38 (0.21–0.66) | 0.001 | 0.37 (0.21–0.67) | 0.002 | 1.29 (0.41–4.11) | 0.66 |
| Grade 3 mucositis | 5.38 (2.16–13.42) | 0.001 | 3.06 (1.94–4.83) | 0.001 | 3.79 (2.35–6.12) | 0.001 | 5.83 (1.50–22.67) | 0.01 |
| Renal toxicity | 1.66 (0.28–10.01) | 0.58 | 4.87 (2.82–8.39) | 0.001 | 5.05 (2.48–10.27) | 0.001 | 3.06 (1.32–7.10) | 0.009 |
ASCT: autologous stem cell transplantation; BEAM: carmustine, etoposide, cytarabine, melphalan; BeEAM: bendamustine, etoposide, cytarabine, melphalan; CI: confidence interval; DLBCL: diffuse large B-cell lymphoma; HL: Hodgkin’s lymphoma; NHL: non-Hodgkin’s lymphoma; NRM: non-relapse mortality; OR: odds ratio; OS: overall survival; PFS: progression free survival; RR: relapse rate.